Grant: Master's Award: Canada Graduate Scholarships
McMaster University
$17,500.00
Developing a Degradation-Resistant ADAMTS13 Variant as a Thrombolytic Therapy for Stroke
FY 2023-24
Summary
Ischemic stroke (IS) is a serious medical condition that occurs when blood clots block the flow of blood to the brain and damages brain tissue. IS is a leading cause of death and disability, impacting more than 77 million individuals worldwide. To treat IS, clinicians can provide a drug that dissolves the blood clots or perform surgery to remove clots from the brain. However, these therapies have had limited success because they are associated with significant risks of brain bleeding that can be more damaging to patient health than the blood clot itself. As a result, the administration of ADAMTS13 has emerged as a potential solution. ADAMTS13 is a circulating protease that cleaves von Willebrand Factor, a key blood clotting protein, to stop the overproduction of blood clots. The use of ADAMTS13 can dissolve established blood clots without causing bleeding in several blood clotting disorders. We believe that ADAMTS13 can treat IS, but ADAMTS13 is prone to breaking down in the blood which reduces its capacity to dissolve blood clots. To overcome these challenges, we engineered ADAMTS13 so that it can dissolve clots without degrading in the blood. Excitingly, our preliminary data shows that the modifications we made to ADAMTS13 does not disrupt its regular function. We hypothesize that this degradation-resistant ADAMTS13 variant can be used to improve treatment outcomes for IS. Therefore, the objective of my project is to evaluate the clot-dissolving ability, therapeutic efficacy, and safety of this ADAMTS13 variant for the treatment of IS. Overall, our findings will provide a better understanding of the potential benefits associated with our degradation-resistant version of ADAMTS13 and directly contribute to the development of safer, more effective therapies for stroke.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
506108
Name
Huang Rex
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Developing a Degradation-Resistant ADAMTS13 Variant as a Thrombolytic Therapy for Stroke
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Adamts13; Adamts13 Degradation; Blood Flow; Hemostasis; Ischemic Stroke; Platelet Accumulation; Stroke Therapy; Thrombolytic; Thrombosis; Tissue Plasminogen Activator
Abstract
Ischemic stroke (IS) is a serious medical condition that occurs when blood clots block the flow of blood to the brain and damages brain tissue. IS is a leading cause of death and disability, impacting more than 77 million individuals worldwide. To treat IS, clinicians can provide a drug that dissolves the blood clots or perform surgery to remove clots from the brain. However, these therapies have had limited success because they are associated with significant risks of brain bleeding that can be more damaging to patient health than the blood clot itself. As a result, the administration of ADAMTS13 has emerged as a potential solution. ADAMTS13 is a circulating protease that cleaves von Willebrand Factor, a key blood clotting protein, to stop the overproduction of blood clots. The use of ADAMTS13 can dissolve established blood clots without causing bleeding in several blood clotting disorders. We believe that ADAMTS13 can treat IS, but ADAMTS13 is prone to breaking down in the blood which reduces its capacity to dissolve blood clots. To overcome these challenges, we engineered ADAMTS13 so that it can dissolve clots without degrading in the blood. Excitingly, our preliminary data shows that the modifications we made to ADAMTS13 does not disrupt its regular function. We hypothesize that this degradation-resistant ADAMTS13 variant can be used to improve treatment outcomes for IS. Therefore, the objective of my project is to evaluate the clot-dissolving ability, therapeutic efficacy, and safety of this ADAMTS13 variant for the treatment of IS. Overall, our findings will provide a better understanding of the potential benefits associated with our degradation-resistant version of ADAMTS13 and directly contribute to the development of safer, more effective therapies for stroke.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Huang, Rex
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~